4/18
04:30 pm
gern
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/11
04:08 pm
gern
Considering The Merits Of A Gamble On Geron Corporation [Seeking Alpha]
Medium
Report
Considering The Merits Of A Gamble On Geron Corporation [Seeking Alpha]
4/11
09:07 am
gern
Geron Corporation (NASDAQ:GERN) Is Expected To Breakeven In The Near Future [Yahoo! Finance]
Medium
Report
Geron Corporation (NASDAQ:GERN) Is Expected To Breakeven In The Near Future [Yahoo! Finance]
4/11
08:06 am
gern
Geron Co. (NASDAQ: GERN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.
Medium
Report
Geron Co. (NASDAQ: GERN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.
4/10
01:19 pm
gern
Geron Co. (NASDAQ: GERN) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $6.00 price target on the stock.
Low
Report
Geron Co. (NASDAQ: GERN) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $6.00 price target on the stock.
4/3
04:30 pm
gern
Geron to Participate at Upcoming Investor Conferences in April
Low
Report
Geron to Participate at Upcoming Investor Conferences in April
3/19
09:20 am
gern
Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
Low
Report
Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
3/19
09:07 am
gern
Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Medium
Report
Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
3/18
03:01 pm
gern
Geron Co. (NASDAQ: GERN) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $6.00 price target on the stock.
Low
Report
Geron Co. (NASDAQ: GERN) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $6.00 price target on the stock.
3/18
02:58 pm
gern
Geron Co. (NASDAQ: GERN) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $4.00 to $5.00. They now have a "buy" rating on the stock.
Low
Report
Geron Co. (NASDAQ: GERN) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $4.00 to $5.00. They now have a "buy" rating on the stock.
3/18
09:17 am
gern
FASHIONGO Unveils The First Dynamic Net Terms for Wholesale [Yahoo! Finance]
High
Report
FASHIONGO Unveils The First Dynamic Net Terms for Wholesale [Yahoo! Finance]
3/15
03:52 pm
gern
Geron, Madrigal Pharmaceuticals jump on good news from FDA [Yahoo! Finance]
Low
Report
Geron, Madrigal Pharmaceuticals jump on good news from FDA [Yahoo! Finance]
3/15
11:05 am
gern
Geron (GERN) Gets ODAC Votes for Blood Disorder Drug, Shares Up [Yahoo! Finance]
Low
Report
Geron (GERN) Gets ODAC Votes for Blood Disorder Drug, Shares Up [Yahoo! Finance]
3/15
10:07 am
gern
Geron surges after FDA AdCom backing for lead drug [Seeking Alpha]
Medium
Report
Geron surges after FDA AdCom backing for lead drug [Seeking Alpha]
3/15
09:36 am
gern
Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy [Seeking Alpha]
High
Report
Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy [Seeking Alpha]
3/15
08:08 am
gern
Geron Co. (NASDAQ: GERN) had its price target raised by analysts at Needham & Company LLC from $4.00 to $5.00. They now have a "buy" rating on the stock.
Medium
Report
Geron Co. (NASDAQ: GERN) had its price target raised by analysts at Needham & Company LLC from $4.00 to $5.00. They now have a "buy" rating on the stock.
3/15
05:50 am
gern
Biggest stock movers today: ADBE, GERN, and more [Seeking Alpha]
Medium
Report
Biggest stock movers today: ADBE, GERN, and more [Seeking Alpha]
3/14
04:21 pm
gern
Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS [Yahoo! Finance]
Medium
Report
Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS [Yahoo! Finance]
3/14
03:54 pm
gern
Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS
Neutral
Report
Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS
3/14
03:49 pm
gern
Geron wins FDA AdCom backing for blood cancer drug [Seeking Alpha]
Neutral
Report
Geron wins FDA AdCom backing for blood cancer drug [Seeking Alpha]
3/14
03:36 pm
gern
UPDATE 1-Geron's blood disorder drug gets FDA advisers' backing [Yahoo! Finance]
Neutral
Report
UPDATE 1-Geron's blood disorder drug gets FDA advisers' backing [Yahoo! Finance]
3/14
03:31 pm
gern
Geron's blood disorder drug gets FDA advisers' backing [Reuters]
Neutral
Report
Geron's blood disorder drug gets FDA advisers' backing [Reuters]
3/12
10:01 am
gern
UPDATE 1-US FDA staff flags concerns about Geron's anemia treatment [Yahoo! Finance]
Medium
Report
UPDATE 1-US FDA staff flags concerns about Geron's anemia treatment [Yahoo! Finance]
3/5
10:40 am
gern
Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA [Seeking Alpha]
Low
Report
Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA [Seeking Alpha]
2/29
10:12 am
gern
Geron Corporation (NASDAQ:GERN) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Geron Corporation (NASDAQ:GERN) Q4 2023 Earnings Call Transcript [Yahoo! Finance]